Transcenta Updates Encouraging Efficacy Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ESMO 2024 ...Middle East

Updated results with longer follow-up reveal confirmed ORR of 68% and median PFS of 14.2 months in patients with CLDN18.2 high or medium expression, known PD-L1 CPS (n=66). PRINCETON, N.J. and SUZHOU, China, Sept. 18, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX:...

Hence then, the article about transcenta updates encouraging efficacy data from first line triple combo trial of osemitamab tst001 for g gej cancer at esmo 2024 was published today ( Thursday 19/09/2024 - 03:09 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Transcenta Updates Encouraging Efficacy Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ESMO 2024 )

Also on site :

• ‘You’re f***ing crazy!’ Trump yelled at Netanyahu for derailing Iran talks – Axios
• Rock Icon Has Major Family News at 82
• 90s Rock Legend Alanis Morissette Celebrates Her 52nd Birthday Today